Theratechnologies Inc
TSX:TH
Theratechnologies Inc
Research & Development
Theratechnologies Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Theratechnologies Inc
TSX:TH
|
Research & Development
-$14.1m
|
CAGR 3-Years
27%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-13%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Research & Development
-CA$11.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-125%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Research & Development
-$29.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-7%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Research & Development
-$272.7m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-34%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Research & Development
-CA$14.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Research & Development
-$94.5m
|
CAGR 3-Years
-83%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Theratechnologies Inc
Glance View
Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).
See Also
What is Theratechnologies Inc's Research & Development?
Research & Development
-14.1m
USD
Based on the financial report for May 31, 2025, Theratechnologies Inc's Research & Development amounts to -14.1m USD.
What is Theratechnologies Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-13%
Over the last year, the Research & Development growth was 26%. The average annual Research & Development growth rates for Theratechnologies Inc have been 27% over the past three years , -1% over the past five years , and -13% over the past ten years .
